mis416
Small moleculeexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2010 (NCT01191996)
Timeline
Indications
Mechanism of action
NOD2 activator
- Toll-like receptor 9ACTIVATOR
TLR9 activator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mis416
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02228213 | Phase 2 | Oct 1, 2014 | INC Research, Innate Immunotherapeutics |
| NCT01191996 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2010 | Innate Immunotherapeutics, National Multiple Sclerosis Society, Primorus Clinical Trials, University of Otago |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Innate Immunotherapeutics | For profit | 2 | 2 | 1 | 2010 |
| INC Research | For profit | 1 | 0 | 1 | 2014 |
| National Multiple Sclerosis Society | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Primorus Clinical Trials | For profit | 1 | 0 | 1 | 2010 |
| University of Otago | Academic/Hospital | 1 | 0 | 1 | 2010 |
5 organizations
Page 1 / 1